NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
November 20 2017 - 4:25PM
NewLink Genetics Corporation (NASDAQ:NLNK) today announced the
presentation of data from a Phase 1 study of indoximod, in
combination with radiation, for children with progressive brain
tumors. These data were presented at the Society for
NeuroOncology, 22nd Annual Meeting, in San Francisco, CA, on
November 19, 2017, by Theodore S. Johnson, M.D., Ph.D., Associate
Professor of Pediatrics at Augusta University.
The presentation entitled, “Radio-chemo-immunotherapy using the
IDO-inhibitor indoximod for children with progressive brain tumors
in the phase 1 setting” showed the combination of indoximod plus
radiation was well-tolerated.
“We are very pleased with early study data combining salvage
radiation therapy with indoximod. This combination seems to
be well-tolerated in children with recurrent brain tumors, despite
their previous treatment with high-dose radiation plans,” said
Theodore S. Johnson, M.D., Ph.D., Associate Professor of Pediatrics
at Augusta University. “We applaud NewLink Genetics for providing
access to indoximod for the children enrolling in this
first-in-children study.”
A link to the presentation slides can be accessed through the
NewLink Genetics website at www.NewLinkGenetics.com in the
"Investors & Media" section under "Events &
Presentations." A second presentation, complete with scan
images, given by Dr. Johnson at the Texas Children’s Neuro-oncology
Conference on November 10, 2017 can be found listed in the same
location on NewLink’s website. Additional information for
this study, NLG2105 for pediatric patients with refractory
malignant brain tumors, may be found here.
About NewLink Genetics
Corporation
NewLink Genetics is a late-stage
biopharmaceutical company focusing on discovering, developing and
commercializing novel immuno-oncology product candidates to improve
the lives of patients with cancer. NewLink Genetics’ IDO
pathway inhibitors are designed to harness multiple components of
the immune system to combat cancer. Indoximod is being
evaluated in combination with treatment regimens including
anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across
multiple indications such as melanoma, pancreatic cancer and other
malignancies. For more information, please visit
www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements of
NewLink that involve substantial risks and uncertainties. All
statements contained in this press release are forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. The words "anticipate," "believe," "estimate,"
"expect," "intend," "may," "plan," "target," "potential," "will,"
"could," "should," "seek" or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements
include, among others, statements about NewLink Genetics' financial
guidance for 2017; results of its clinical trials for product
candidates; its timing of release of data from ongoing clinical
studies; its plans related to moving additional indications into
clinical development; NewLink Genetics' future financial
performance, results of operations, cash position and sufficiency
of capital resources to fund its operating requirements; and any
other statements other than statements of historical fact.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that NewLink makes due to a number of important factors,
including those risks discussed in "Risk Factors" and elsewhere in
NewLink Genetics' Annual Report on Form 10-K for the year ended
December 31, 2016 and other reports filed with the U.S. Securities
and Exchange Commission (SEC). The forward-looking statements
in this press release represent NewLink's views as of the date of
this press release. NewLink anticipates that subsequent events and
developments will cause its views to change. However, while
it may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to do
so. You should, therefore, not rely on these forward-looking
statements as representing NewLink Genetics' views as of any date
subsequent to the date of this press release.
Investor Contact:Lisa MillerDirector of Investor
RelationsNewLink Genetics(515) 598-2555lmiller@linkp.com
Media Contact:Andrew MastrangeloAVP, Public & Media
RelationsLaVoieHealthScience617-374-8800, ext.
108amastrangelo@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024